Accès ouvert
2024
article
OpenAlex
Jonghwa Lee, Jessica L. Beers, Isabel Cheng, Vivian Truong et autres
Venetoclax is a first-in-class orally administered B-cell lymphoma-2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its major metabolite M27, via M5, and M2, M3, and M4 via oxidation. …
us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Anthony R. Mato, Bilal Manzoor, C. C. Coombs, Nicole Lamanna et autres
Background: Treatment (tx) options for patients (pts) with chronic/small lymphocytic leukemia (CLL/SLL) have expanded following regulatory approval of targeted agents. However, real-world evidence regarding pt outcomes and tx sequences is evolving. Aims: We assessed tx trends, sequences and outcomes following the introduction …
us, Afrique du Sud, de, ca, in, gb
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
J. P. Sharman, W. Jurczak, C. C. Coombs, M. Hill et autres
Background: Covalent Bruton Tyrosine Kinase (BTK) inhibitors (BTKi) have transformed the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but these treatments are not curative and many patients will require additional treatment. Covalent BTKi share pharmacologic liabilities (e.g. low oral …
us, pl, it
(code pays fourni par la source)